Copyright
©The Author(s) 2017.
World J Methodol. Mar 26, 2017; 7(1): 9-15
Published online Mar 26, 2017. doi: 10.5662/wjm.v7.i1.9
Published online Mar 26, 2017. doi: 10.5662/wjm.v7.i1.9
Table 3 Chromogranin A diagnostic accuracy in neuroendocrine tumor studies
Type (no pts) | CgA cut-off | Sensitivity (%) | Specificity (%) | Ref. |
NET (128) | 100 μg/L | 59 | 68 | [57] |
NET (127) | 34.7 u/L | 67.9 | 85.7 | [35] |
NET (80) | 17 u/L | 56.3 | 100 | [58] |
NET (63) | 34 u/L | 55 | 94 | [59] |
GEP/NET (61) | 20 u/L | 92 | 83 | [50] |
100 u/L | 47 | 99 | ||
GEP/NET (124) | 130 μg/L | 62.9 | 98.4 | [16] |
GEP/NET (202) | 53 ng/mL | 71.3 | 77.8 | [60] |
NET (120) | 98 ng/mL | 79 | NA | [61] |
GEP/NET (119) | 2.8 nmol/L | 92.9 | 100 | [62] |
- Citation: Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol 2017; 7(1): 9-15
- URL: https://www.wjgnet.com/2222-0682/full/v7/i1/9.htm
- DOI: https://dx.doi.org/10.5662/wjm.v7.i1.9